Clinical Trial Update: Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing eflornithine plus lomustine versus lomustine alone in recurrent anaplastic astrocytoma patients; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma

Drugs mentioned

• Lomustine (Lomustine)
• eflornithine + lomustine

Snippet

Sponsor: Orbus Therapeutics, Inc. | Conditions: Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma | Phase 3 | Status: UNKNOWN